Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Operating Officer | March 01, 2023 | March 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,500 |
Reported balance
After 2023-03-01 transaction · row 1
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 52,500 · Balance 52,500 F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.87 · Expires 2033-03-01 | Direct | 297,500 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 297,500 · Balance 297,500 F2: The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer.
F2: The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 297,500 | $0.00 Strike: $18.87 | $0.00 |
DisclosureSEC source: 0001725160-23-000050 · wf-form4_167779259154330.xml · derivative · entry 2 Roth Iris · CIK 0001964808 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,500 Underlying: Common Stock · 297,500 shares Expires 2033-03-01 F2 · derivative.exercise_date: The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000050 · wf-form4_167779259154330.xml · nonDerivative · entry 1 Roth Iris · CIK 0001964808 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.